Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TERIPARATIDE vs NATPARA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Teriparatide is a recombinant fragment of human parathyroid hormone (PTH 1-34). It acts by stimulating osteoblast activity, increasing bone formation, and improving bone microarchitecture.
Recombinant human parathyroid hormone (PTH 1-84) that binds to PTH1 receptors, increasing serum calcium by enhancing renal calcium reabsorption, intestinal calcium absorption, and bone resorption.
Treatment of postmenopausal women with osteoporosis at high risk for fracture,Treatment of men with primary or hypogonadal osteoporosis at high risk for fracture,Treatment of men and women with glucocorticoid-induced osteoporosis at high risk for fracture
Hypoparathyroidism
20 mcg subcutaneously once daily.
Initial dose: 50 mcg subcutaneously once daily, titrate in 25 mcg increments every 2-4 weeks based on serum calcium and symptoms, maintenance dose range: 25-100 mcg once daily.
Terminal half-life approximately 1 hour following subcutaneous administration; clinical duration limited by rapid clearance, necessitating once-daily dosing.
Terminal half-life approximately 2–5 minutes (subcutaneous); rapid clearance with clinical context: requires twice-daily dosing due to short half-life
Teriparatide is metabolized via non-specific proteolytic degradation in the liver and peripheral tissues. No specific cytochrome P450 enzymes are involved.
Metabolized in the liver via proteolytic cleavage, primarily by cathepsin D and other proteases.
Primarily hepatic metabolism via nonspecific proteolytic enzymes; no significant renal or biliary excretion; minimal unchanged drug in urine or feces.
Primarily renal (≥95% as intact parathyroid hormone and metabolites); biliary/fecal elimination minimal (<5%)
Approximately 40-50% bound to plasma proteins, primarily albumin.
Approximately 55–60% bound to plasma proteins, primarily albumin
Approximately 0.2-0.3 L/kg, indicating distribution largely confined to extracellular fluid and bone.
Approximately 0.1–0.2 L/kg; reflects limited extravascular distribution, primarily in plasma and interstitial space
Subcutaneous: approximately 95% bioavailability.
Subcutaneous: approximately 55% (relative to intravenous injection)
No dose adjustment required for mild to moderate renal impairment (Cr Cl >30 m L/min). Not recommended in severe renal impairment (Cr Cl ≤30 m L/min) due to lack of data.
e GFR <30 m L/min/1.73 m2: initiate at 25 mcg daily, titrate cautiously; e GFR 30-59: no specific adjustment but monitor calcium; e GFR ≥60: no adjustment.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh class A or B). Not studied in severe hepatic impairment (Child-Pugh class C).
No formal studies; use with caution in severe hepatic impairment (Child-Pugh C) with increased monitoring.
Not approved for use in pediatric patients; safety and efficacy not established.
Not approved for patients <18 years; safety and efficacy not established.
No dose adjustment required; clinical studies included patients >65 years with no significant differences in efficacy or safety.
No specific dose adjustment; consider age-related renal decline and lower starting dose (25 mcg).
Increased risk of osteosarcoma in animal studies. Avoid use in patients with Paget's disease of bone, unexplained elevations of alkaline phosphatase, open epiphyses, prior radiation therapy involving the skeleton, or bone metastases.
None.
Risk of osteosarcoma (see black box warning),Orthostatic hypotension may occur, especially with initial doses,Hypercalcemia may occur; monitor serum calcium,Use with caution in patients with active urolithiasis,May increase serum uric acid
Risk of osteosarcoma (increased with duration of use; avoid in patients with increased baseline risk),Digitalis toxicity,Hypocalcemia exacerbation upon discontinuation,Hypercalcemia and hypercalciuria requiring monitoring,Hypomagnesemia,Hypotension with rapid IV administration (not approved IV),Laboratory test interference (unlikely)
Paget's disease of bone,Unexplained elevations of alkaline phosphatase,Open epiphyses (pediatric patients),Prior radiation therapy involving the skeleton,Bone metastases or history of skeletal malignancies,Metabolic bone diseases other than osteoporosis,Pregnancy and lactation,Hypersensitivity to teriparatide or any component
Hypersensitivity to recombinant human PTH or any component,Pre-existing hypercalcemia,Metabolic bone diseases (e.g., Paget's disease),Radiation therapy to skeleton (increased osteosarcoma risk),Skeletal malignancies or bone metastases,Pediatric patients with open epiphyses
No specific food interactions. However, ensure adequate dietary calcium and vitamin D intake (e.g., dairy products, green leafy vegetables, fortified foods) to support the anabolic effect. Avoid excessive sodium, protein, and caffeine, which may increase calcium excretion. Do not take calcium supplements within 2 hours of teriparatide injection if instructed to take them separately, though generally they can be taken together.
Avoid excessive dietary calcium intake beyond prescribed supplements as it may increase risk of hypercalcemia. High-oxalate foods (e.g., spinach, rhubarb, beets) may reduce calcium absorption; separate intake from calcium supplements by at least 2 hours. Foods high in phosphorus (e.g., dairy, nuts, whole grains) may affect calcium balance; maintain consistent intake. Do not consume high-dose vitamin D or vitamin A without medical supervision.
Insufficient human data; animal studies show skeletal abnormalities at high doses. No known risk in first trimester; avoid in second and third trimesters due to potential fetal skeletal effects.
NATPARA (parathyroid hormone) is classified as Pregnancy Category C. In animal studies, parathyroid hormone has been associated with reduced fetal weight and skeletal abnormalities when administered during organogenesis. There are no adequate and well-controlled studies in pregnant women. The risk is likely highest during the first trimester due to skeletal development. Exposure in the second and third trimesters may affect fetal calcium homeostasis, but specific human data are lacking. Use only if potential benefit justifies potential risk to the fetus.
No human data; teriparatide likely excreted in milk in low amounts. M/P ratio unknown. Recommend caution or avoid breastfeeding.
It is unknown if parathyroid hormone is excreted in human milk. No human lactation studies are available. The molecular weight (4117 Da) suggests minimal excretion, but due to potential for adverse effects in the nursing infant, caution is advised. The M/P ratio is unknown. Consider the importance of the drug to the mother and decide whether to discontinue nursing or discontinue the drug.
No dose adjustment recommended based on pharmacokinetic changes; however, use only if potential benefit justifies risk.
No specific dose adjustment guidelines exist for NATPARA in pregnancy. However, due to increased plasma volume and altered calcium metabolism during pregnancy, closer monitoring of serum calcium is required, and dose adjustments may be necessary to maintain target calcium levels within the normal range. Start with the lowest effective dose and titrate based on serum calcium response, typically every 2–4 weeks.
Teriparatide is a recombinant human parathyroid hormone analog used for osteoporosis. It is the only anabolic agent that stimulates new bone formation. Administer as a subcutaneous injection in the thigh or abdomen. Rotate injection sites. Do not use in patients with Paget's disease, unexplained alkaline phosphatase elevation, prior radiation therapy to the skeleton, or bone metastases. Maximum duration of therapy is 24 months over a patient's lifetime due to an increased risk of osteosarcoma in rats. Monitor serum calcium levels at baseline and periodically; may cause transient hypercalcemia 4-6 hours after dosing. Contraindicated in hypercalcemia, pregnancy, and lactation.
NATPARA (parathyroid hormone) is a recombinant human PTH(1-84) used as an adjunct to calcium and vitamin D in hypoparathyroidism. Monitor serum calcium closely after initiation; adjust concomitant calcium and vitamin D doses to avoid hypercalcemia. Discontinue if serum calcium exceeds 12 mg/d L. Patients with renal impairment are at increased risk of hypercalcemia. Not recommended in patients with Paget's disease or skeletal metastases due to risk of osteosarcoma (based on animal studies). Store at 2-8°C; do not freeze. Administer via subcutaneous injection into the thigh using the provided pen device.
Store teriparatide in the refrigerator at 2-8°C (36-46°F) and never freeze. Protect from light and do not use if the solution is cloudy, colored, or contains particles.,Inject once daily using the provided pen device. Administer at the same time each day, preferably in the morning, into the thigh or abdomen. Rotate injection sites to avoid lipodystrophy.,Sit or lie down during the first few doses if you experience dizziness or rapid heartbeat, as teriparatide may cause orthostatic hypotension. Stand up slowly.,Do not use teriparatide for more than 24 months total over your lifetime. Inform your doctor if you have Paget's disease, a history of radiation therapy, or bone cancer.,Contact your doctor if you have persistent nausea, vomiting, constipation, muscle weakness, or confusion, as these may be signs of hypercalcemia.,Take calcium and vitamin D supplements as recommended by your doctor, typically 1000 mg calcium and 800 IU vitamin D daily, to support bone formation.
NATPARA is used to increase low calcium levels by replacing parathyroid hormone.,You must take calcium and vitamin D supplements as directed; do not stop them unless instructed.,Inject NATPARA into the thigh exactly as prescribed, using a new needle each time.,Store the pen in the refrigerator at 2-8°C; do not freeze or shake.,Common side effects include nausea, diarrhea, and injection site reactions.,Report symptoms of high calcium: nausea, vomiting, constipation, muscle weakness, or confusion.,Avoid taking thiazide diuretics (e.g., hydrochlorothiazide) without doctor approval as they can raise calcium levels.,Do not use if you have Paget's disease, bone cancer, or have had radiation to bones.,Keep all appointments for blood tests to monitor calcium and kidney function.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TERIPARATIDE vs NATPARA, answered by our medical review team.
TERIPARATIDE is a Parathyroid Hormone Analog that works by Teriparatide is a recombinant fragment of human parathyroid hormone (PTH 1-34). It acts by stimulating osteoblast activity, increasing bone formation, and improving bone microarchitecture.. NATPARA is a Parathyroid Hormone Analog that works by Recombinant human parathyroid hormone (PTH 1-84) that binds to PTH1 receptors, increasing serum calcium by enhancing renal calcium reabsorption, intestinal calcium absorption, and bone resorption.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TERIPARATIDE and NATPARA depend on the specific clinical indication. These are both Parathyroid Hormone Analog agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TERIPARATIDE is: 20 mcg subcutaneously once daily.. The standard adult dose of NATPARA is: Initial dose: 50 mcg subcutaneously once daily, titrate in 25 mcg increments every 2-4 weeks based on serum calcium and symptoms, maintenance dose range: 25-100 mcg once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TERIPARATIDE and NATPARA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TERIPARATIDE is classified as Category A/B. Insufficient human data; animal studies show skeletal abnormalities at high doses. No known risk in first trimester; avoid in second and third trimesters due to potential fetal ske. NATPARA is classified as Category C. NATPARA (parathyroid hormone) is classified as Pregnancy Category C. In animal studies, parathyroid hormone has been associated with reduced fetal weight and skeletal abnormalities. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.